MODIFICATION
B -- Leadership Development Program
- Notice Date
- 6/9/2005
- Notice Type
- Modification
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, MD, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- Reference-Number-D8770205
- Response Due
- 6/14/2005
- Archive Date
- 6/29/2005
- Point of Contact
- Tracy O'Neill, Contract Specialist, Phone 301-827-7175, Fax 301-827-7106,
- E-Mail Address
-
toneill@oc.fda.gov
- Small Business Set-Aside
- Total Small Business
- Description
- This is a combined synopsis/solicitation for commercial items or services prepared in accordance with the format in FAR Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a written solicitation will not be issued. This solicitation is issued as a Request for Quote (RFQ) No. D8770205. These solicitation clauses and provisions are those in effect through Federal Acquisition Circular 97-27. The North American Classification System (NAICS) Code is 541990. The proposed acquisition is a total small business set-aside. The Food and Drug Administration’s Office of Clinical Pharmacology and Biopharmaceutics (OCPB) plans to implement cultural, strategic and tactical changes based on the foundational training all managers received in leadership development during 2004 and early 2005. The contractor shall provide consulting services to plan, administer, coach, train, debrief, and facilitate all managers in the “OCPB Leadership Development Program.” THERE IS A PREFERENCE FOR the contractor to be a primary engagement partner trained in pharmacy or clinical pharmacology practice and leadership development. The consultant will need to perform The Scope of Work, which is to include: Facilitate the implementation of a leadership development program for managers and reviewers; Administer Individual Leadership Assessment profiles by launching an electronic tool for following individual performance development in leadership skills to between 35 and 120 reviewers and managers over the duration of the program; Provide unlimited coaching sessions to managers and reviewers (approximately 35 participants on site and/or by telephone) in response to Individual Leadership Assessment Profile results and a previously conducted cultural survey. Coaching sessions should facilitate the application of the leadership and communication skills learned to increasing self awareness and development; Provide group training and debrief to managers and reviewers in separate forums if needed on results of an individual leadership assessment tool; Conduct two leadership workshops for 35 to 110 reviewers and/or leaders related to leadership development without authority and authentic conversations. Workshop participants would practice using a framework to prepare for and walk through a conversation in a way that issues can emerge and solutions are generated. These workshops may be combined with other elements of the plan and conducted off-site; Produce and facilitate the development and implementation of a written, dynamic strategic plan during 2005 including training reviewers and managers in a series of meetings on developing the initial components of the strategic plan; Provide coaching, administration, planning, and training to reviewers and managers on the administration of a performance management tool in which managers commit to support reviewers in performance goals that support the strategic goals of the Office, Center and Agency. The planning and training would launch a review process for individual development plan goals; Conduct four performance dialogue training seminars for reviewers and managers in groups of 20 to 35 participants; Conduct a training session for managers and reviewers to engage in a productive change management process; Conduct four conflict resolutions and management seminars for all reviewers and managers in groups of 20; and Administer a leadership cultural survey at the beginning and end of the process in order to assess progress in leadership development. Contractor shall work closely with Center for Drug Evaluation and Research staff and other appropriate Food and Drug Administration (FDA) staff. Deliverables: The contractor shall submit the following reports/deliverables: (1) a) Written Strategic Plan Delivery with strategy, support, coaching and training required for implementation and b) Performance Management Tool Implementation with the majority of managers having engaged in providing their supports and reports a written commitment of performance support and initiated a dialog regarding that commitment. (2) Preparation and Administration of Individual Leadership Assessment Profiles: Train reviewers and managers on using the electronic individual leadership assessment tool, tool would be administered to managers and reviewers and results sent out for analysis. (3) Workshop: Leadership Without Authority Workshop. A) Individual debriefing and unlimited coaching on Individual Leadership Assessment Profiles – combination of workshop and one-on-one coaching to enable personal debrief on TLC results. (4) Change Management Training Session: Session to provide training in a productive engagement in change management as new organizational structure begins. (5) Four Performance Dialog Seminars: should be conducted in groups of 20 to 35 participants with managers trained separately from direct reports and supports. (6) Workshop: Authentic Conversations Workshop – must be highly interactive and include opportunities to practice the skill. (7) Written Report on Progress in Leadership Development Program. (8) Four Conflict Resolution and Conflict Management Seminars – Interactive seminars in groups of 20 participants. (9) Site Visit observation of Leadership Staff meeting and meeting with organizational customers and unlimited coaching to a) reinforce performance support project b) reinforce new structure and implementation of strategic plan. (10) Administration of follow up cultural survey – a comparison report and assessment should be presented by engagement partner. (11) Debrief with Managers and Reviewers on follow up cultural survey and coaching sessions – debrief to be conducted during existing Divisional and Office level meetings. Coaching sessions are to be individually scheduled with reviewers and managers. (12) Written report on Progress in Leadership Development Program and Strategic Plan Progress. Evaluation Criteria is as follows: Government will award an order resulting from this request for quotation to the vendor whose quote represents the best value to the Government Past Performance, Technical, and Price will be considered. Past Performance: Provide information for three past or current projects completed with the past seven years that are similar in size, scope and complexity to the work required. Each reference should include A). Name and address of client organizations. Client organizations should be those composed of clinical pharmacologists or pharmacists. B) Contract Number, if applicable; C) Name, Title, Telephone number and Fax Numbers and e-mail address of a currently available client point of contact/reference; D) Description of work performed E) Performance period and F) Dollar value. All technical an past performance proposals shall be limited to 50 pages, 8 x 11 paper, single spaced, size 12 font. Technical: (1)Training in Leadership development and practical experience. Training in healthcare field with preference to experience as a registered pharmacist or clinical pharmacologist with clinical experience and practical leadership experience in management of pharmacists and/or clinical pharmacologists in a clinical healthcare environment. [40] (2) Practical experience in developing and coaching the implementation of a strategic plan for healthcare field and/or with preference to experience in a pharmaceutical organization (government or non-profit) (excluding pharmaceutical firm experience) composed primarily of pharmacists and/or clinical pharmacologists. [30] (3) Ability and experience providing leadership development seminars and long term development programs [10] (4) Performance dialogue discussion and coaching sessions [10] (5) Conflict management and coaching interactive sessions [10] The FDA intends to make an award immediately following the due date of this notice. The period of performance will be approximately sixteen (16) months. The following FAR Clauses shall apply to this solicitation: 52.212-1, 52.212-2, 52.212-4, 52.212-5 Instructions to Offerors-Commercial; 52.214-4 Contract Terms and Conditions-Commercial Items; and 52.232-33 Electronic Funds Transfers. All responsible sources that can provide and meet the above requirements shall submit statement of capabilities and written quotations by the due date referenced above. All questions should be submitted in writing via e-mail to TONEILL@OC.FDA.GOV or fax to 301-827-7106. FAR provisions can be found at the following website: http://www/arnet.gov. NOTE: THIS NOTICE WAS NOT POSTED TO WWW.FEDBIZOPPS.GOV ON THE DATE INDICATED IN THE NOTICE ITSELF (09-JUN-2005); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/FDA/DCASC/Reference-Number-D8770205/listing.html)
- Place of Performance
- Address: FDA/CDER/Office of Clinical Pharmacology and Biopharmaceutics (OCPB) 5600 Fishers Lane, Room 6A-19, HFD-850 Rockville, MD
- Zip Code: 20857
- Country: USA
- Zip Code: 20857
- Record
- SN00826378-F 20050611/050609214121 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |